From May 18 to 19, 2017, the 3rd BFC Healthcare Industry Business Development and Investment Cooperation Exchange Conference was held at the Grand Hyatt Shanghai. Our company was invited to participate in this BFC HealthCare Investment Cooperation Exchange Conference. At the conference, our company gave a focused presentation on the R&D progress of our pipeline new drug projects, technology transfer to external parties, and our corporate development strategy, attracting widespread attention from attending investors and business partners. In addition, senior executives from our company held one-on-one meetings with several well-known institutional investors and outstanding enterprises in the biopharmaceutical R&D sector, discussing topics such as our company’s development and future financing needs, as well as trends and conditions in both domestic and international pharmaceutical markets, thereby establishing initial cooperative relationships and reaching preliminary intentions for collaboration.

The BFC Healthcare Forum is hosted by BFC Group, a boutique investment bank specializing in cross-border business cooperation, cross-border investments, and mergers and acquisitions in the healthcare sector. The forum aims to create a platform for companies in the healthcare industry to explore business development partnerships and for investment institutions to identify investment opportunities. This conference brings together over a hundred well-known and rapidly growing companies in the healthcare sector, including Shandong Henry, Buchang Pharmaceutical, Harbin Pharmaceutical Group, Bio-Thera Solutions, and NORTHLAND, which will participate in corporate roadshows. Additionally, more than a hundred investment institutions involved in the healthcare sector, such as Sequoia Capital China Fund, Jinpu Health Fund, Xinyuan Capital, and Qiancao Capital, will also attend the event.